No Data
Goldman Sachs: Oral weight loss drugs will be one of the most promising new medications in recent years!
Goldman Sachs predicts that by 2030, oral weight loss drugs will account for 24% of the total weight loss drug market, and Eli Lilly and Co will lead this segment with its orforglipron. Next, pay close attention to the third-quarter results of the ATTAIN-1 trial announced by Eli Lilly, which will be the first reading of orforglipron in the field of obesity and the most important next catalyst for the oral obesity drug market.
Here's the Major Earnings Before the Open Tomorrow
Nasdaq, S&P, Dow Observed Limited Moves as Markets Closed Near Even With Earnings on Deck
Plaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications
Tariffs Bite Dan Loeb's Portfolio: Thermo Fisher Hit Hard, Discover Shines
Visa, Mastercard Earnings Expected to Show Solid Y/Y Growth Amid Tariff Uncertainty
